[Surveying the status of continuous blood purification technology application in Chinese pediatric intensive care unit].
OBJECTIVE
To learn application status of continuous blood purification (CBP) in pediatric intensive care unit (PICU), to provide reference to promote the development of CBP technology.


METHODS
The survey of CBP application was conducted using questionnaire in 40 hospitals providing intensive care, which included children's hospitals and the pediatric sections of general hospitals from 28 provinces/municipalities/autonomous regions in China during March to July of 2012.


RESULTS
Totally 38 hospital replied, 25 hospitals carried out CBP technology, first carried out in 1997, the median year was 2008, 21 hospitals' PICU could independently carry out CBP device, 18 hospitals had the nurses who could professionally operate, routinely maintain the device. Continuous veno-venous hemodiafiltration was the largest implementation mode of CBP, accounting for 51.9%. Twenty-three hospitals used ordinary heparin, and 2 hospitals used low molecular weight heparin; 21 hospitals chose activated partial thromboplastin time as the coagulation testing, due to lack of equipment, only four hospitals chose activated clotting time as coagulation testing. Only 3 hospitals could apply before and after dilution joint technology. Kidney failure is still the disease accounting for the highest proportion of diseases requiring CBP application, accounting for 38.1%, followed by sepsis, 19.1%, drug poisoning 16.7%.


CONCLUSIONS
CBP started 10 years ago, and got attention and promotion nearly five years ago in China, but the associated personnel, equipment were inadequate, anticoagulation, before and after dilution and other technical applications were not complete enough, high volume hemofiltration mode was seldom used.
Department of Pediatric Emergency Medicine, Children's Hospital of Fudan University, Shanghai 201102, China.
Leilei
L
Li
Department of Pediatric Emergency Medicine, Children's Hospital of Fudan University, Shanghai 201102, China. Email: luxy2005@yahoo.com.
Guoping
G
Lu
D000925:Anticoagulants / Q000008:administration & dosage; D002648:Child; D002681:China / Q000453:epidemiology; D006440:Hemofiltration / Q000379:methods / Q000706:statistics & numerical data; D006493:Heparin / Q000008:administration & dosage; D006776:Hospitals, Pediatric; D006801:Humans; D007223:Infant; D015278:Intensive Care Units, Pediatric; D010314:Partial Thromboplastin Time; D006435:Renal Dialysis / Q000379:methods*; D051437:Renal Insufficiency / Q000628:therapy*; D018805:Sepsis / Q000628:therapy*; D011795:Surveys and Questionnaires
D000925:Anticoagulants; D006493:Heparin